Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous

The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow‐up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast‐enhancing regions may appe...

Full description

Saved in:

Bibliographic Details
Published in:	NMR in biomedicine Vol. 37; no. 4; pp. e5095 - n/a
Main Authors:	Ungan, Gülnur, Pons‐Escoda, Albert, Ulinic, Daniel, Arús, Carles, Ortega‐Martorell, Sandra, Olier, Ivan, Vellido, Alfredo, Majós, Carles, Julià‐Sapé, Margarida
Format:	Journal Article
Language:	English
Published:	England Wiley Subscription Services, Inc 01.04.2024
Subjects:	Biomarkers Chemotherapy convex non‐negative matrix factorization Evaluation Glioblastoma Heterogeneity Lesions Metabolism MRS pseudoprogression Radiation therapy Temozolomide pseudoprogression convex non-negative matrix factorization glioblastoma MR MRS
ISSN:	0952-3480, 1099-1492, 1099-1492
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!